image
Healthcare - Biotechnology - NASDAQ - US
$ 0.519
-12.1 %
$ 32.1 M
Market Cap
-0.38
P/E
1. INTRINSIC VALUE

Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A.[ Read More ]

The intrinsic value of one PASG stock under the base case scenario is HIDDEN Compared to the current market price of 0.519 USD, Passage Bio, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart PASG

image
FINANCIALS
0 REVENUE
0.00%
-108 M OPERATING INCOME
21.68%
-102 M NET INCOME
25.02%
-78.3 M OPERATING CASH FLOW
33.79%
65.2 M INVESTING CASH FLOW
158.89%
135 K FINANCING CASH FLOW
10077.83%
0 REVENUE
0.00%
-20.7 M OPERATING INCOME
-19.13%
-19.3 M NET INCOME
-20.94%
-7.45 M OPERATING CASH FLOW
43.31%
15 M INVESTING CASH FLOW
1328.34%
0 FINANCING CASH FLOW
0.00%
Balance Sheet Decomposition Passage Bio, Inc.
image
Current Assets 118 M
Cash & Short-Term Investments 114 M
Receivables 0
Other Current Assets 3.66 M
Non-Current Assets 32.6 M
Long-Term Investments 0
PP&E 32.2 M
Other Non-Current Assets 433 K
Current Liabilities 16.3 M
Accounts Payable 1.3 M
Short-Term Debt 6.75 M
Other Current Liabilities 8.3 M
Non-Current Liabilities 22.9 M
Long-Term Debt 22.9 M
Other Non-Current Liabilities 0
EFFICIENCY
Earnings Waterfall Passage Bio, Inc.
image
Revenue 0
Cost Of Revenue 3.72 M
Gross Profit -3.72 M
Operating Expenses 108 M
Operating Income -108 M
Other Expenses -6.33 M
Net Income -102 M
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-91.71% ROE
-91.71%
-67.80% ROA
-67.80%
-94.53% ROIC
-94.53%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Passage Bio, Inc.
image
Net Income -102 M
Depreciation & Amortization 3.72 M
Capital Expenditures -146 K
Stock-Based Compensation 10.9 M
Change in Working Capital 5.34 M
Others 11.9 M
Free Cash Flow -78.4 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Passage Bio, Inc.
image
PASG has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Passage Bio, Inc.
image
Sold
0-3 MONTHS
175 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
3.01 K USD 2
9-12 MONTHS
38.5 K USD 3
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
1 month ago
Sep 19, 2024
Sell 27.9 K USD
ORBIMED ADVISORS LLC
10 percent owner
- 39300
0.71 USD
2 months ago
Sep 16, 2024
Sell 46.7 K USD
ORBIMED ADVISORS LLC
10 percent owner
- 63100
0.74 USD
2 months ago
Sep 17, 2024
Sell 81.3 K USD
ORBIMED ADVISORS LLC
10 percent owner
- 111400
0.73 USD
1 month ago
Sep 18, 2024
Sell 18.7 K USD
ORBIMED ADVISORS LLC
10 percent owner
- 25631
0.73 USD
9 months ago
Feb 13, 2024
Sell 1.43 K USD
Borthwick Kathleen
SVP, INTERIM CFO
- 1470
0.97 USD
9 months ago
Feb 13, 2024
Sell 1.59 K USD
Forman Mark S
CHIEF MEDICAL OFFICER
- 1638
0.97 USD
10 months ago
Jan 02, 2024
Sell 14.4 K USD
Forman Mark S
Chief Medical Officer
- 15813
0.91 USD
10 months ago
Jan 02, 2024
Sell 9.71 K USD
Borthwick Kathleen
SVP, Interim CFO
- 10672
0.91 USD
10 months ago
Jan 02, 2024
Sell 14.4 K USD
Cale Edgar B.
GC & Corporate Secretary
- 15813
0.91 USD
1 year ago
Jul 28, 2023
Sell 10.1 K USD
King Simona
Chief Financial Officer
- 11453
0.88 USD
1 year ago
Jun 28, 2023
Bought 483 K USD
ORBIMED ADVISORS LLC
10 percent owner
+ 575195
0.84 USD
1 year ago
Jun 27, 2023
Bought 519 K USD
ORBIMED ADVISORS LLC
10 percent owner
+ 617382
0.84 USD
1 year ago
Jun 16, 2023
Sell 3.78 K USD
Fotopoulos Alexandros
Chief Technical Officer
- 4052
0.9325 USD
1 year ago
Apr 18, 2023
Sell 2.16 K USD
King Simona
Chief Financial Officer
- 2053
1.05 USD
1 year ago
Dec 01, 2022
Sell 5.96 K USD
Kapadia Sandip
Director
- 5000
1.1929 USD
1 year ago
Nov 22, 2022
Sell 4.95 K USD
Fotopoulos Alexandros
Chief Technical Officer
- 3720
1.33 USD
2 years ago
Sep 19, 2022
Sell 2.54 K USD
Toernsen Monika Maria
Chief Commercial Officer
- 1681
1.5105 USD
2 years ago
May 04, 2022
Bought 589 K USD
ORBIMED ADVISORS LLC
10 percent owner
+ 303500
1.94 USD
2 years ago
May 03, 2022
Bought 427 K USD
OrbiMed Capital GP VII LLC
director:
+ 221500
1.93 USD
2 years ago
May 03, 2022
Bought 427 K USD
ORBIMED ADVISORS LLC
10 percent owner
+ 221500
1.93 USD
2 years ago
Jan 20, 2022
Bought 254 K USD
ORBIMED ADVISORS LLC
10 percent owner
+ 50800
5 USD
2 years ago
Mar 21, 2022
Bought 31.5 K USD
Goldsmith Bruce A
CEO and President
+ 10000
3.15 USD
2 years ago
Jan 20, 2022
Bought 2 M USD
ORBIMED ADVISORS LLC
10 percent owner
+ 369100
5.42 USD
2 years ago
Jan 19, 2022
Bought 221 K USD
ORBIMED ADVISORS LLC
10 percent owner
+ 43300
5.11 USD
2 years ago
Jan 18, 2022
Bought 626 K USD
ORBIMED ADVISORS LLC
10 percent owner
+ 114700
5.46 USD
2 years ago
Jan 14, 2022
Bought 57.7 K USD
ORBIMED ADVISORS LLC
10 percent owner
+ 10300
5.6 USD
2 years ago
Jan 13, 2022
Bought 231 K USD
ORBIMED ADVISORS LLC
10 percent owner
+ 41800
5.52 USD
2 years ago
Jan 12, 2022
Bought 565 K USD
ORBIMED ADVISORS LLC
10 percent owner
+ 100000
5.65 USD
2 years ago
Jan 11, 2022
Bought 45.3 K USD
ORBIMED ADVISORS LLC
10 percent owner
+ 8200
5.53 USD
3 years ago
May 21, 2021
Bought 30 K USD
Morris Richard Steven
Chief Financial Officer
+ 2171
13.8183 USD
3 years ago
May 21, 2021
Bought 26.2 K USD
Goldsmith Bruce A
CEO and President
+ 2000
13.115 USD
3 years ago
Mar 15, 2021
Sell 176 K USD
Romano Gary
Chief Medical Officer
- 8383
20.9546 USD
3 years ago
Mar 15, 2021
Sell 35.4 K USD
Romano Gary
Chief Medical Officer
- 1617
21.8616 USD
3 years ago
Jan 20, 2021
Sell 39 K USD
Quigley Jill M.
Chief Operating Officer
- 1300
30.0085 USD
3 years ago
Jan 14, 2021
Sell 491 K USD
Quigley Jill M.
Chief Operating Officer
- 16298
30.1 USD
4 years ago
Mar 24, 2020
Bought 150 K USD
Countouriotis Athena
Director
+ 10000
14.975 USD
4 years ago
Mar 03, 2020
Bought 9.9 M USD
Ratcliffe Liam
Director
+ 550000
18 USD
4 years ago
Mar 03, 2020
Bought 50.4 K USD
Ratcliffe Liam
Director
+ 2800
18 USD
4 years ago
Feb 28, 2020
Bought 6.72 M USD
ORBIMED ADVISORS LLC
10 percent owner
+ 373300
18 USD
4 years ago
Mar 03, 2020
Bought 4.05 M USD
Versant Venture Capital VI, L.P.
10 percent owner
+ 225000
18 USD
4 years ago
Mar 03, 2020
Bought 9.9 M USD
Frazier Life Sciences IX, L.P.
10 percent owner
+ 550000
18 USD
4 years ago
Mar 03, 2020
Bought 4.05 M USD
Woiwode Thomas
director, 10 percent owner:
+ 225000
18 USD
4 years ago
Mar 03, 2020
Bought 9.9 M USD
Heron Patrick J
director, 10 percent owner:
+ 550000
18 USD
4 years ago
Mar 03, 2020
Bought 117 K USD
Yamada Tadataka
Director
+ 6500
18 USD
4 years ago
Mar 03, 2020
Bought 50.4 K USD
Ratcliffe Liam
Director
+ 2800
18 USD
4 years ago
Mar 03, 2020
Bought 27 K USD
Quigley Jill M.
Chief Operating Officer
+ 1500
18 USD
4 years ago
Mar 03, 2020
Bought 18 K USD
Quigley Jill M.
Chief Operating Officer
+ 1000
18 USD
4 years ago
Mar 03, 2020
Bought 7.2 K USD
Morris Richard Steven
Chief Financial Officer
+ 400
18 USD
4 years ago
Mar 03, 2020
Bought 90 K USD
Kapadia Sandip
Director
+ 5000
18 USD
4 years ago
Mar 03, 2020
Bought 90 K USD
Islam Saqib
Director
+ 5000
18 USD
4 years ago
Mar 03, 2020
Bought 19.8 K USD
Goldsmith Bruce A
CEO and President
+ 1100
18 USD
4 years ago
Mar 03, 2020
Bought 99 K USD
Fotopoulos Alexandros
Chief Technical Officer
+ 5500
18 USD
4 years ago
Mar 03, 2020
Bought 160 K USD
Countouriotis Athena
Director
+ 8900
18 USD
4 years ago
Mar 03, 2020
Bought 36 K USD
Cale Edgar B.
GC and Corporate Secretary
+ 2000
18 USD
7. News
Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference PHILADELPHIA , Nov. 06, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will present at Guggenheim Securities Healthcare Innovation Conference on Wednesday, November 13, 2024 at 2:30 p.m. ET. globenewswire.com - 1 week ago
Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference Preclinical data demonstrated that an AAV1 vector achieved superior human progranulin levels in the CSF as compared to AAV5 and AAVhu68 (an AAV9 variant) globenewswire.com - 3 weeks ago
Passage Bio to Present at Chardan's 8th Annual Genetic Medicines Conference PHILADELPHIA, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will present at Chardan's 8th Annual Genetic Medicines Conference on Tuesday, October 1, 2024 at 8:30 a.m. ET. globenewswire.com - 1 month ago
Passage Bio Welcomes Tom Kassberg to Board of Directors PHILADELPHIA, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced the appointment of Tom Kassberg to the Board of Directors and his appointment to the Audit Committee. Mr. Kassberg is currently Chief Business Officer and Executive Vice President at Ultragenyx, a biopharmaceutical company committed to bringing novel therapies to patients for the treatment of serious rare and ultrarare genetic diseases. globenewswire.com - 2 months ago
Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference PHILADELPHIA, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9, 2024 at 7:00 a.m. ET. globenewswire.com - 2 months ago
Passage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights Enrolled first FTD-GRN patient in Cohort 2 in upliFT-D trial Plan to present updated safety and biomarker data from Cohort 1 FTD-GRN patients treated with PBFT02 at 14th International Conference on Frontotemporal Dementias (ISFTD2024) in September 2024 Achieved alignment with Food and Drug Administration (FDA) on the company's proposed clinical development plans to expand the upliFT-D trial to assess PBFT02 in FTD patients with C9orf72 gene mutations Completed out-licensing of pediatric lysosomal storage disease programs to GEMMA Biotherapeutics Strong balance sheet to support continued execution, with cash runway to fund operations extended to the end of Q2 2026 PHILADELPHIA, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today reported financial results for the second quarter ended June 30, 2024 and provided recent business highlights. “This has been a pivotal quarter for our company, marked by significant momentum in our upliFT-D trial, increased clarity around our strategy to expand PBFT02 into additional adult neurodegenerative indications, and out-licensing of our pediatric lysosomal storage disorder programs,” said Will Chou, M.D. globenewswire.com - 3 months ago
Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration Granted exclusive, worldwide rights for the development and commercialization of PBGM01 for GM1 gangliosidosis, PBKR03 for Krabbe disease, and PBML04 for metachromatic leukodystrophy to GEMMA Biotherapeutics, a new company co-founded by Dr. James M. Wilson globenewswire.com - 3 months ago
Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients Agency feedback from Type C meeting process supports the company's proposed clinical development plans to expand the upliFT-D trial to assess PBFT02 in FTD patients with C9orf72 gene mutations globenewswire.com - 4 months ago
Passage Bio (PASG) Loses -22.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner The heavy selling pressure might have exhausted for Passage Bio (PASG) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. zacks.com - 4 months ago
Passage Bio to Present at Goldman Sachs 45th Annual Global Healthcare Conference PHILADELPHIA, June 05, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that William Chou, M.D., president and chief executive officer, will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024 at 4:00 p.m. ET. globenewswire.com - 5 months ago
Passage Bio Announces Recipient of Third Annual Tachi Yamada Scholarship Award PHILADELPHIA, May 21, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced Carrie Gordon, a sophomore at Drexel University, as the third recipient of its Tachi Yamada Scholarship award. globenewswire.com - 5 months ago
All You Need to Know About Passage Bio (PASG) Rating Upgrade to Buy Passage Bio (PASG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com - 6 months ago
8. Profile Summary

Passage Bio, Inc. PASG

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 32.1 M
Dividend Yield 0.00%
Description Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Contact One Commerce Square, Philadelphia, PA, 19103 https://www.passagebio.com
IPO Date Feb. 28, 2020
Employees 58
Officers Dr. Sue Browne Ph.D. Senior Vice President of Research & Development Eden Fucci Senior Vice President of Technical Operations Dr. Karl Whitney Ph.D. Senior Vice President of Global Regulatory Affairs Ms. Kathleen Borthwick Senior Vice President, Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer Mr. Stuart M. Henderson Senior Vice President of Corporate Development & Investor Relations Dr. James M. Wilson M.D., Ph.D. Co-Founder & Chief Scientific Advisor Dr. William Chou M.D. President, Chief Executive Officer & Director Mr. Edgar B. Cale Esq., J.D. General Counsel & Company Secretary